[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @Biopharma_Watch BiopharmaWatch BiopharmaWatch posts on X about nasdaq, $imab, $osrh, $oncy the most. They currently have XXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::1734221906151165952/interactions)  - X Week XXXXX -XX% - X Month XXXXXX +37% - X Months XXXXXX -XX% - X Year XXXXXXX +420% ### Mentions: XX [#](/creator/twitter::1734221906151165952/posts_active)  - X Week XX -XX% - X Month XXX +36% - X Months XXX +888% - X Year XXX +1,377% ### Followers: XXX [#](/creator/twitter::1734221906151165952/followers)  - X Week XXX +4.30% - X Month XXX +11% - X Months XXX +51% - X Year XXX +84% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::1734221906151165952/influencer_rank)  ### Social Influence [#](/creator/twitter::1734221906151165952/influence) --- **Social category influence** [exchanges](/list/exchanges) XXXX% [stocks](/list/stocks) XXXX% [finance](/list/finance) XXXX% [cryptocurrencies](/list/cryptocurrencies) XXXX% **Social topic influence** [nasdaq](/topic/nasdaq) 2.78%, [$imab](/topic/$imab) 1.85%, [$osrh](/topic/$osrh) 1.85%, [$oncy](/topic/$oncy) 1.85%, [$tlx](/topic/$tlx) 1.85%, [$7846t](/topic/$7846t) 0.93%, [$adtx](/topic/$adtx) 0.93%, [$cgtx](/topic/$cgtx) 0.93%, [$anvs](/topic/$anvs) 0.93%, [$rnaz](/topic/$rnaz) XXXX% **Top assets mentioned** [Bruker, Corp. (BRKR)](/topic/$brkr) [Apellis Pharmaceuticals, Inc. Common Stock (APLS)](/topic/$apls) [IDEAYA Biosciences, Inc. Common Stock (IDYA)](/topic/$idya) [Alkermes Inc. plc (ALKS)](/topic/$alks) [Regeneron Pharmaceuticals Inc (REGN)](/topic/$regn) [Bristol-Myers Squibb Co (BMY)](/topic/$bmy) [Public Masterpiece Token (PMT)](/topic/$pmt) [Oobit (OBT)](/topic/$obt) [GLOBUS MEDICAL INC (GMED)](/topic/$gmed) ### Top Social Posts [#](/creator/twitter::1734221906151165952/posts) --- Top posts by engagements in the last XX hours "$ADTX 1.31$ XXXX% July XX 2025 Aditxts Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic Ovarian Test"  [@Biopharma_Watch](/creator/x/Biopharma_Watch) on [X](/post/tweet/1948409119670710424) 2025-07-24 15:45:08 UTC XXX followers, XX engagements "Top Market Movers: Positive News Full Access: $CGTX 0.75$ XXXX% July XX 2025 Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesines Protection of Neurons and Synapses in Alzheimers Disease"  [@Biopharma_Watch](/creator/x/Biopharma_Watch) on [X](/post/tweet/1947684317205041554) 2025-07-22 15:45:02 UTC XXX followers, XXX engagements "Latest catalysts: $ANVS Catalyst Date - 2025-07-27 Drug - buntanetap Treatment - Alzheimer's disease"  [@Biopharma_Watch](/creator/x/Biopharma_Watch) on [X](/post/tweet/1948771486229299686) 2025-07-25 15:45:03 UTC XXX followers, XXX engagements "Unusual Volume Ticker - Avg Vol - Cur Vol - Unusual Ratio $ANEB - 689.0K - 20.1M - XXXXX $CLSD - 8.3M - 227.9M - XXXXX $RNAZ - 164.0K - 4.2M - 25.42"  [@Biopharma_Watch](/creator/x/Biopharma_Watch) on [X](/post/tweet/1948409098451714053) 2025-07-24 15:45:03 UTC XXX followers, XXX engagements "$APYX 2.48$ XXXX% July XX 2025 Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2025 Financial Results on August X 2025"  [@Biopharma_Watch](/creator/x/Biopharma_Watch) on [X](/post/tweet/1948771509583097903) 2025-07-25 15:45:08 UTC XXX followers, XX engagements "Sionna Therapeutics (NASDAQ: $SION) is making waves in a tough biotech IPO market. The company just raised $219M in its IPO targeting cystic fibrosis (CF) with a novel undruggable approach. Their therapies could restore near-normal CFTR function for over XX% of CF patients addressing gaps left by current treatments. Key points: Positive Phase X data for lead candidates SION-719 and SION-451 with Phase 2a trials starting soon Global CF therapy market projected to reach $39B by 2034 Strong cash runway through 2028 all analysts rate Sionna a Buy Major milestone: mid-2026 clinical data readout"  [@Biopharma_Watch](/creator/x/Biopharma_Watch) on [X](/post/tweet/1948427594489364784) 2025-07-24 16:58:33 UTC XXX followers, XXX engagements "$BRKR 35.80$ -XXXXX% July XX 2025 Bruker Announces Second Quarter 2025 Preliminary Results Plans to Hold Q2 Earnings Conference Call on August X 2025"  [@Biopharma_Watch](/creator/x/Biopharma_Watch) on [X](/post/tweet/1947321948998136218) 2025-07-21 15:45:06 UTC XXX followers, XX engagements "Latest catalysts: $IMAB Catalyst Date - 2025-07-08 Drug - Givastomig (TJ033721 / ABL111) Treatment - Claudin 18.2-positive gastric cancers"  [@Biopharma_Watch](/creator/x/Biopharma_Watch) on [X](/post/tweet/1942248509824204984) 2025-07-07 15:45:04 UTC XXX followers, XXX engagements "Top Market Movers: Positive News Full Access: $OSRH 1.01$ XXXX% July XX 2025 OSR Holdings Enters into Term Sheet to Acquire Woori IO a Pioneer in Noninvasive Glucose Monitoring Technology"  [@Biopharma_Watch](/creator/x/Biopharma_Watch) on [X](/post/tweet/1948771481015779454) 2025-07-25 15:45:02 UTC XXX followers, XXX engagements "$APLS Catalyst Date - 2025-07-28 Drug - EMPAVELI (pegcetacoplan) Treatment - C3 glomerulopathy primary immune complex membranoproliferative glomerulonephritis"  [@Biopharma_Watch](/creator/x/Biopharma_Watch) on [X](/post/tweet/1948771531662000501) 2025-07-25 15:45:14 UTC XXX followers, XXX engagements "$IDYA 23.27$ XXXX% July XX 2025 IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849) a Potential First-in-Class DLL3-TOP1 ADC"  [@Biopharma_Watch](/creator/x/Biopharma_Watch) on [X](/post/tweet/1948046733600301270) 2025-07-23 15:45:08 UTC XXX followers, XX engagements "Top Market Movers: Positive News Full Access: $PSTV 0.62$ XXXXX% July XX 2025 Plus Therapeutics Announces $XXX Million Advance Payment from CPRIT"  [@Biopharma_Watch](/creator/x/Biopharma_Watch) on [X](/post/tweet/1948409093380829201) 2025-07-24 15:45:02 UTC XXX followers, XXX engagements "Latest catalysts: $IMAB Catalyst Date - 2025-07-02 Drug - Givastomig (Claudin XXXX x 4-1BB bispecific antibody) Treatment - Claudin 18.2-positive metastatic gastric cancers"  [@Biopharma_Watch](/creator/x/Biopharma_Watch) on [X](/post/tweet/1940074177643569655) 2025-07-01 15:45:03 UTC XXX followers, XXX engagements "Top Market Movers: Negative News Full Access: $EVO 3.66$ -XXXXX% July XX 2025 Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance"  [@Biopharma_Watch](/creator/x/Biopharma_Watch) on [X](/post/tweet/1947321934708080842) 2025-07-21 15:45:03 UTC XXX followers, XXX engagements "$ALKS 26.50$ -XXXX% July XX 2025 Alkermes Announces Positive Topline Results From Vibrance-1 Phase X Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1"  [@Biopharma_Watch](/creator/x/Biopharma_Watch) on [X](/post/tweet/1947321959748075912) 2025-07-21 15:45:09 UTC XXX followers, XXX engagements "$ONCY 1.18$ -XXXX% July XX 2025 Oncolytics Biotech Regains Compliance with Nasdaq Trading Rules"  [@Biopharma_Watch](/creator/x/Biopharma_Watch) on [X](/post/tweet/1948046735802347960) 2025-07-23 15:45:09 UTC XXX followers, XX engagements "$ONCY 1.18$ -XXXX% July XX 2025 Oncolytics Biotech Regains Compliance with Nasdaq Trading Rules"  [@Biopharma_Watch](/creator/x/Biopharma_Watch) on [X](/post/tweet/1948046752453726375) 2025-07-23 15:45:13 UTC XXX followers, XXX engagements "$OSRH 1.08$ XXXX% July XX 2025 OSR Holdings Enters into Term Sheet to Acquire Woori IO a Pioneer in Noninvasive Glucose Monitoring Technology"  [@Biopharma_Watch](/creator/x/Biopharma_Watch) on [X](/post/tweet/1948409129137279260) 2025-07-24 15:45:10 UTC XXX followers, XXX engagements "$ATYR 6.71$ XXXXX% July XX 2025 aTyr Pharma Announces Last Patient Visit in Phase X EFZO-FIT Study of Efzofitimod in Patients with Pulmonary Sarcoidosis"  [@Biopharma_Watch](/creator/x/Biopharma_Watch) on [X](/post/tweet/1948046707532685633) 2025-07-23 15:45:02 UTC XXX followers, XXX engagements "Top Market Movers: Positive News Full Access: $ABVX 65.61$ XXXXXX% July XX 2025 Abivax Announces Positive Phase X Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod its First-in-Class Oral miR-124 En"  [@Biopharma_Watch](/creator/x/Biopharma_Watch) on [X](/post/tweet/1948046706513424601) 2025-07-23 15:45:02 UTC XXX followers, XXX engagements "Top Market Movers: Negative News Full Access: $TLX 14.47$ -XXXXX% July XX 2025 Telix Reports $204M Revenue Up XX% YOY"  [@Biopharma_Watch](/creator/x/Biopharma_Watch) on [X](/post/tweet/1948046710162506113) 2025-07-23 15:45:03 UTC XXX followers, XXX engagements "Upcoming catalysts to watch in April 2025 📅: $RAPT $PMN $CLNN $GNTA $BOLD $THTX $REGN $BMY $NBTX $AMPG $BCAK $EOSI $EVAX $TLX $OCGN $SNTI $KURA $PMT $OBT For detailed insights 📷"  [@Biopharma_Watch](/creator/x/Biopharma_Watch) on [X](/post/tweet/1908846399388533049) 2025-04-06 11:37:00 UTC XXX followers, XXX engagements "$GMED 53.30$ XXXX% July XX 2025 Globus Medical Announces Leadership Transitions and Preliminary Second Quarter 2025 Sales Results"  [@Biopharma_Watch](/creator/x/Biopharma_Watch) on [X](/post/tweet/1947684361874378800) 2025-07-22 15:45:12 UTC XXX followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
BiopharmaWatch posts on X about nasdaq, $imab, $osrh, $oncy the most. They currently have XXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.
Social category influence exchanges XXXX% stocks XXXX% finance XXXX% cryptocurrencies XXXX%
Social topic influence nasdaq 2.78%, $imab 1.85%, $osrh 1.85%, $oncy 1.85%, $tlx 1.85%, $7846t 0.93%, $adtx 0.93%, $cgtx 0.93%, $anvs 0.93%, $rnaz XXXX%
Top assets mentioned Bruker, Corp. (BRKR) Apellis Pharmaceuticals, Inc. Common Stock (APLS) IDEAYA Biosciences, Inc. Common Stock (IDYA) Alkermes Inc. plc (ALKS) Regeneron Pharmaceuticals Inc (REGN) Bristol-Myers Squibb Co (BMY) Public Masterpiece Token (PMT) Oobit (OBT) GLOBUS MEDICAL INC (GMED)
Top posts by engagements in the last XX hours
"$ADTX 1.31$ XXXX% July XX 2025 Aditxts Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic Ovarian Test" @Biopharma_Watch on X 2025-07-24 15:45:08 UTC XXX followers, XX engagements
"Top Market Movers: Positive News Full Access: $CGTX 0.75$ XXXX% July XX 2025 Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesines Protection of Neurons and Synapses in Alzheimers Disease" @Biopharma_Watch on X 2025-07-22 15:45:02 UTC XXX followers, XXX engagements
"Latest catalysts: $ANVS Catalyst Date - 2025-07-27 Drug - buntanetap Treatment - Alzheimer's disease" @Biopharma_Watch on X 2025-07-25 15:45:03 UTC XXX followers, XXX engagements
"Unusual Volume Ticker - Avg Vol - Cur Vol - Unusual Ratio $ANEB - 689.0K - 20.1M - XXXXX $CLSD - 8.3M - 227.9M - XXXXX $RNAZ - 164.0K - 4.2M - 25.42" @Biopharma_Watch on X 2025-07-24 15:45:03 UTC XXX followers, XXX engagements
"$APYX 2.48$ XXXX% July XX 2025 Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2025 Financial Results on August X 2025" @Biopharma_Watch on X 2025-07-25 15:45:08 UTC XXX followers, XX engagements
"Sionna Therapeutics (NASDAQ: $SION) is making waves in a tough biotech IPO market. The company just raised $219M in its IPO targeting cystic fibrosis (CF) with a novel undruggable approach. Their therapies could restore near-normal CFTR function for over XX% of CF patients addressing gaps left by current treatments. Key points: Positive Phase X data for lead candidates SION-719 and SION-451 with Phase 2a trials starting soon Global CF therapy market projected to reach $39B by 2034 Strong cash runway through 2028 all analysts rate Sionna a Buy Major milestone: mid-2026 clinical data readout" @Biopharma_Watch on X 2025-07-24 16:58:33 UTC XXX followers, XXX engagements
"$BRKR 35.80$ -XXXXX% July XX 2025 Bruker Announces Second Quarter 2025 Preliminary Results Plans to Hold Q2 Earnings Conference Call on August X 2025" @Biopharma_Watch on X 2025-07-21 15:45:06 UTC XXX followers, XX engagements
"Latest catalysts: $IMAB Catalyst Date - 2025-07-08 Drug - Givastomig (TJ033721 / ABL111) Treatment - Claudin 18.2-positive gastric cancers" @Biopharma_Watch on X 2025-07-07 15:45:04 UTC XXX followers, XXX engagements
"Top Market Movers: Positive News Full Access: $OSRH 1.01$ XXXX% July XX 2025 OSR Holdings Enters into Term Sheet to Acquire Woori IO a Pioneer in Noninvasive Glucose Monitoring Technology" @Biopharma_Watch on X 2025-07-25 15:45:02 UTC XXX followers, XXX engagements
"$APLS Catalyst Date - 2025-07-28 Drug - EMPAVELI (pegcetacoplan) Treatment - C3 glomerulopathy primary immune complex membranoproliferative glomerulonephritis" @Biopharma_Watch on X 2025-07-25 15:45:14 UTC XXX followers, XXX engagements
"$IDYA 23.27$ XXXX% July XX 2025 IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849) a Potential First-in-Class DLL3-TOP1 ADC" @Biopharma_Watch on X 2025-07-23 15:45:08 UTC XXX followers, XX engagements
"Top Market Movers: Positive News Full Access: $PSTV 0.62$ XXXXX% July XX 2025 Plus Therapeutics Announces $XXX Million Advance Payment from CPRIT" @Biopharma_Watch on X 2025-07-24 15:45:02 UTC XXX followers, XXX engagements
"Latest catalysts: $IMAB Catalyst Date - 2025-07-02 Drug - Givastomig (Claudin XXXX x 4-1BB bispecific antibody) Treatment - Claudin 18.2-positive metastatic gastric cancers" @Biopharma_Watch on X 2025-07-01 15:45:03 UTC XXX followers, XXX engagements
"Top Market Movers: Negative News Full Access: $EVO 3.66$ -XXXXX% July XX 2025 Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance" @Biopharma_Watch on X 2025-07-21 15:45:03 UTC XXX followers, XXX engagements
"$ALKS 26.50$ -XXXX% July XX 2025 Alkermes Announces Positive Topline Results From Vibrance-1 Phase X Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1" @Biopharma_Watch on X 2025-07-21 15:45:09 UTC XXX followers, XXX engagements
"$ONCY 1.18$ -XXXX% July XX 2025 Oncolytics Biotech Regains Compliance with Nasdaq Trading Rules" @Biopharma_Watch on X 2025-07-23 15:45:09 UTC XXX followers, XX engagements
"$ONCY 1.18$ -XXXX% July XX 2025 Oncolytics Biotech Regains Compliance with Nasdaq Trading Rules" @Biopharma_Watch on X 2025-07-23 15:45:13 UTC XXX followers, XXX engagements
"$OSRH 1.08$ XXXX% July XX 2025 OSR Holdings Enters into Term Sheet to Acquire Woori IO a Pioneer in Noninvasive Glucose Monitoring Technology" @Biopharma_Watch on X 2025-07-24 15:45:10 UTC XXX followers, XXX engagements
"$ATYR 6.71$ XXXXX% July XX 2025 aTyr Pharma Announces Last Patient Visit in Phase X EFZO-FIT Study of Efzofitimod in Patients with Pulmonary Sarcoidosis" @Biopharma_Watch on X 2025-07-23 15:45:02 UTC XXX followers, XXX engagements
"Top Market Movers: Positive News Full Access: $ABVX 65.61$ XXXXXX% July XX 2025 Abivax Announces Positive Phase X Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod its First-in-Class Oral miR-124 En" @Biopharma_Watch on X 2025-07-23 15:45:02 UTC XXX followers, XXX engagements
"Top Market Movers: Negative News Full Access: $TLX 14.47$ -XXXXX% July XX 2025 Telix Reports $204M Revenue Up XX% YOY" @Biopharma_Watch on X 2025-07-23 15:45:03 UTC XXX followers, XXX engagements
"Upcoming catalysts to watch in April 2025 📅: $RAPT $PMN $CLNN $GNTA $BOLD $THTX $REGN $BMY $NBTX $AMPG $BCAK $EOSI $EVAX $TLX $OCGN $SNTI $KURA $PMT $OBT For detailed insights 📷" @Biopharma_Watch on X 2025-04-06 11:37:00 UTC XXX followers, XXX engagements
"$GMED 53.30$ XXXX% July XX 2025 Globus Medical Announces Leadership Transitions and Preliminary Second Quarter 2025 Sales Results" @Biopharma_Watch on X 2025-07-22 15:45:12 UTC XXX followers, XXX engagements
/creator/x::Biopharma_Watch